Anti-CD138 chimeric antigen receptor T cell therapy(Yake Biotechnology)

N/A

Report date: 2022/10/25 17:50:37

Base Information

Drug NameAnti-CD138 chimeric antigen receptor T cell therapy(Yake Biotechnology)

Drug Alias NameCAR-T CD-138

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD138 +[4]

TargetsSyndecan-1

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesShanghai YaKe Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A